Are you over 18 and want to see adult content?
More Annotations
Paiq · Ontmoet leuke singles · Ontmoet leuke singles
Are you over 18 and want to see adult content?
Best Web Application Development Company | Smart Smith
Are you over 18 and want to see adult content?
Our Happy Hive - Practical Tips To A Sweeter Family Life
Are you over 18 and want to see adult content?
Saint Loup Géanges - SAINT LOUP GÉANGES
Are you over 18 and want to see adult content?
Premium Early Gender Scan - 5D/4D/3D Baby Ultrasound Melbourne
Are you over 18 and want to see adult content?
Home | Learn about your card • Earn points worth chances • Win cash prizes • PayPerks
Are you over 18 and want to see adult content?
A complete backup of beamer-discount.de
Are you over 18 and want to see adult content?
Favourite Annotations
Sinh viên trường đại học nông nghiệp Việt Nam | Hau1.edu.vn
Are you over 18 and want to see adult content?
San José Museum of Art | See what you think.
Are you over 18 and want to see adult content?
AlMiSoft TraXEx - Internet Spurenverwischer
Are you over 18 and want to see adult content?
KennaZ Consultórios Psicopedagógicos Terapêuticos Transpessoais.
Are you over 18 and want to see adult content?
Autos.com: The best autos ranking site to help you find your perfect car
Are you over 18 and want to see adult content?
BMW of Minnetonka | BMW Dealer in Minnetonka, MN
Are you over 18 and want to see adult content?
Text
TERUMO REPORTS
"Terumo Information" for investors. Terumo Reports are available onthis page.
REPORT LIBRARY
Sustainability at the Terumo Group. Resolving Healthcare Challenges. Ensuring the Safety and Quality of Products and Services. Managing Supply Chains That Support Stable Supply /. Promoting Responsible Procurement. Creating Workplace Environments Where Diverse TERUMO BLOOD AND CELL TECHNOLOGIES AND CSL PLASMA ANNOUNCE April 19, 2021. LAKEWOOD, COLO., and BOCA RATON, Fla., U.S.A. - APRIL 19, 2021 - Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. SENDING "HOPE" WITH COLLABORATION ACROSS BORDERS SWIFTLY Linguistically, ECMO is often confused with heart-lung machines and ventilators. Generally, heart-lung machines are large instruments used to replace the functions of the heart and lungs when performing heart surgeries during which the heart is stopped. #06 TERUMO BAY AREA INNOVATION LAB A PLACE TO CREATE NEW Informing Terumo Technology, and this page introduces the story #06 Terumo Bay Area Innovation Lab A place to create new value. #03 TECHNOLOGY THAT MEETS PATIENTS’ MEDICATION NEEDS WITH Alliances with pharmaceutical companies contribute to improved drug delivery. As biopharmaceuticals become widely used throughout the world, Terumo focuses great efforts into its Alliance business: Partnering with pharmaceutical companies in the development and manufacturing technology of administration devices, so that needed drugs are delivered and properly administered to patients. TERUMO LAUNCHES HEARTSHEET®: A GLOBAL FIRST CELLULAR AND June 6, 2016. Terumo Corporation (Headquarters: Tokyo, Japan; President and CEO: Yutaro Shintaku) announced today that in late May it commenced sales of HeartSheet - a global first cellular and tissue-based product designed for the treatment of heart failure.. HeartSheet is designed for treating severe heart failure caused by chronic ischemic heart disease. TERUMO GLOBAL WEBSITEBUSINESS OVERVIEW TOPTIS DIVISION(TERUMO INTERVENTIONAL SYSTEMS) This is the Terumo Group global website; Terumo corporate information, business introductions, and IR, sustainability, and Global Network information are available here. INVESTORS | TERUMO GLOBALTERUMO REPORTFINANCIAL INFORMATION Financial Results for the Fiscal Year Ended 3/2021. May 12, 2021 TERUMO 100TH ANNIVERSARY WEBSITE Terumo 100th Anniversary Website. 100 years have passed since Terumo’s foundation. Its debut product, the domestically produced safe, high-quality thermometer, was launched on the market in the hope of delivering it to as many people as possible. Under the corporate mission; Contributing to Society through Healthcare, we have sinceTERUMO REPORTS
"Terumo Information" for investors. Terumo Reports are available onthis page.
REPORT LIBRARY
Sustainability at the Terumo Group. Resolving Healthcare Challenges. Ensuring the Safety and Quality of Products and Services. Managing Supply Chains That Support Stable Supply /. Promoting Responsible Procurement. Creating Workplace Environments Where Diverse TERUMO BLOOD AND CELL TECHNOLOGIES AND CSL PLASMA ANNOUNCE April 19, 2021. LAKEWOOD, COLO., and BOCA RATON, Fla., U.S.A. - APRIL 19, 2021 - Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. SENDING "HOPE" WITH COLLABORATION ACROSS BORDERS SWIFTLY Linguistically, ECMO is often confused with heart-lung machines and ventilators. Generally, heart-lung machines are large instruments used to replace the functions of the heart and lungs when performing heart surgeries during which the heart is stopped. #06 TERUMO BAY AREA INNOVATION LAB A PLACE TO CREATE NEW Informing Terumo Technology, and this page introduces the story #06 Terumo Bay Area Innovation Lab A place to create new value. #03 TECHNOLOGY THAT MEETS PATIENTS’ MEDICATION NEEDS WITH Alliances with pharmaceutical companies contribute to improved drug delivery. As biopharmaceuticals become widely used throughout the world, Terumo focuses great efforts into its Alliance business: Partnering with pharmaceutical companies in the development and manufacturing technology of administration devices, so that needed drugs are delivered and properly administered to patients. TERUMO LAUNCHES HEARTSHEET®: A GLOBAL FIRST CELLULAR AND June 6, 2016. Terumo Corporation (Headquarters: Tokyo, Japan; President and CEO: Yutaro Shintaku) announced today that in late May it commenced sales of HeartSheet - a global first cellular and tissue-based product designed for the treatment of heart failure.. HeartSheet is designed for treating severe heart failure caused by chronic ischemic heart disease. SITE MAP | TERUMO GLOBAL This page is the Terumo website Site Map. Business Overview. TIS Division (Terumo Interventional Systems) Neurovascular Division(MicroVention)
FINANCIAL INFORMATION "Terumo Information" for investors. Financial Information is availableon this page.
FINANCIAL STATEMENTS Financial Results for FYE 3/2020 (1.6 MB) Financial Results for FYE 3/2020 : Reference (163.9 KB) 3rd Quarter Financial Results for FYE 3/2020 (1.2 MB) 3rd Quarter Financial Results for FYE 3/2020 : Reference (128.3 KB) 1st Half Financial Results for FYE 3/2020 (494.6KB)
REPORT LIBRARY
Sustainability at the Terumo Group. Resolving Healthcare Challenges. Ensuring the Safety and Quality of Products and Services. Managing Supply Chains That Support Stable Supply /. Promoting Responsible Procurement. Creating Workplace Environments Where Diverse TERUMO ENTERS 100TH ANNIVERSARY YEAR January 5, 2021. TOKYO, JAPAN - January 5, 2021 - Terumo Corporation (TSE: 4543) is celebrating its 100 th anniversary this year - marking 100 years of 'Contributing to Society through Healthcare' on September 17, 2021. The company has established 'Stride Ahead' as a slogan, to celebrate and connect all Terumo associates around the world. TERUMO SIGNS A DEFINITIVE AGREEMENT TO ACQUIRE ALL ASSETS February 24, 2021. TOKYO, JAPAN - February 24, 2021 - Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS).HOS specializes in predictive analytics and clinical decision support that enable healthcare organizations to deliver personalized, predictive insights at the point of careTERUMO STORY
Dr. Kitasato studied under Dr. Robert Koch, known for isolating Vibrio cholera (the bacteria that causes cholera), in Germany in the late 19th century. Among other accomplishments, Dr. Kitasato discovered a serum therapy for tetanus and was a world-class physician and researcher nominated for the Nobel Prize. How did this distinguishedman come
TERUMO STORY
Terumo decided to develop an electronic blood pressure monitor for the home-use, that are trusted by doctors due to their high accuracy, and are also easy to use. The development concept was drawn up and the technical associates went to work. In October 1988, Terumo launched an electronic blood pressure monitor that worked at the touch of a TERUMO LAUNCHES NEW SURGICAL SEALANT AQUABRID® IN EMEA AQUABRID® is a fully synthetic surgical sealant developed for aortic surgical procedures. When in contact with water, it reacts and forms a strong, elastic layer within three to five minutes. This makes it ideal for use in wet conditions -- AQUABRID® can be applied directly to wet natural and/or artificial tissue (e.g., an aortic graft). 5,8. JAPAN | GLOBAL NETWORK | TERUMO GLOBAL The regulatory approval status and availability of Terumo Group products differs by country and region. You can receive product and service information from the Terumo Group company operating in the country or region where you will use the products or services. TERUMO GLOBAL WEBSITESearch
*
About Terumo
About Terumo
* About Terumo Top
* Dear Stakeholders
* Terumo Group Identity * Terumo Group Code of Conduct* Corporate Profile
* Corporate Governance* Compliance
* Regulations and Standards * Directors and Executive Officers* History
* Procurement ActivityBack
*
Business Overview
Business Overview
* Business Overview Top * TIS Division(Terumo Interventional Systems) * Neurovascular Division (MicroVention)*
Cardiovascular Division (Terumo Cardiovascular) / HeartSheet Division * Cardiovascular Division (Terumo Cardiovascular) * HeartSheet Division * Vascular Graft Division (Terumo Aortic) * Hospital Systems Division* Alliance Division
* Blood and Cell Technologies Company (Terumo Blood and CellTechnologies)
Back
*
Technology
Technology
* Technology Top
*
Basic Information
* Basic Information Top * Research and Development * Production and Supply * Intellectual Property* Terumo Fellows
* Stories - Our TechnologiesBack
*
Sustainability
Sustainability
* Sustainability Top* News
* Message from Top Management * Sustainability at the Terumo Group * Resolving Healthcare Challenges * Creating a Diverse and Inclusive Workplace * Reducing Environmental Footprint * Serving Our Communities*
Report Library
* Report Library Top* Back Numbers
* GRI Standards IndexBack
*
Investors
Investors
* Investors Top
*
Management Policy
* Management Policy Top * Top Management Message* IR Policy
* Business Risks
*
Financial Information * Financial Information Top* Quarterly Results
* Financial Highlights * Segment Information*
Shareholders & Stock * Shareholders & Stock Top* Stock Information
* Shareholder Return* Chart
* Credit Ratings and Corporate Bond* Analyst Coverage
* Shareholders Meeting * Articles of Incorporation*
IR Library
* IR Library Top
* Financial Statements* Presentations
*
Terumo Reports
* Terumo Reports Top* Back Numbers
* IR Events
* Mail for IR Inquiry* Disclaimer
Back
*
Our Stories
Our Stories
* Our Stories Top
Back
*
Newsroom
Newsroom
* 2020
* 2019
* 2018
* 2017
* 2016
* 2015
* 2014
* 2013
* 2012
* 2011
* 2010
Back
*
Global Network
Global Network
* Global Network Top* Japan
* North America
* South America
* Europe, Middle East and Africa* Greater China
* Asia and Pacific
Back
*
*
*
*
*
*
*
*
Terumo's Response to COVID-19 PLEASE SELECT YOUR REGION Terumo Group provides products and services in over 160 countries and regions. Information about our products and services is available on regional and company-specific websites.* EMEA
* Greater China
* Asia
* Japan
* North America
* South America
TOPICS
*
Sustainability
Our efforts to make a meaningful difference for sustainable society*
Business Overview
Our seven business areas and main products*
Terumo Report 2020
For the fiscal year ended March 31, 2020 EU-MDR SAFETY AND PERFORMANCE INFORMATION Click here for safety and performance information on Terumo products required under the EU Medical Devices Regulation. Terumo Labeling WebsiteNEWSROOM
View all
*
November 16, 2020
General Hospital
Diabeloop SA. and Terumo Corporation Enter into Joint Development Agreement with Exclusive Distribution Right for DBLG1 Automated Insulin Delivery Solution in Japanese Market*
November 9, 2020
General Hospital
Terumo Receives CE Mark for MEDISAFE WITH Japan’s First Patch Pump for Insulin Delivery*
November 5, 2020
Financial
Terumo Revises its Full-Year Financial Guidance for FY2020*
October 22, 2020
Corporate
Terumo Creates Global Group Music*
September 30, 2020
Cardiac and Vascular Terumo India Introduces New 'Phygital' Model of Terumo India Skill Lab to Advance Medical and Clinical SkillsWHAT'S NEW
View all
*
November 9, 2020
IR
Q&A regarding Financial Results for the First Half of FYE 3/2021*
November 6, 2020
IR
Reference regarding Financial Results for the First Half of FYE 3/2021*
November 6, 2020
IR
Audio webcast regarding Financial Results for the First Half of FYE3/2021
*
November 5, 2020
IR
Presentation regarding Financial Results for the First Half of FYE3/2021
*
November 5, 2020
IR
1st Half Financial Results for FYE 3/2021T
O
P
* Terms and Conditions of Use* Site Map
* Privacy Policy
* Social Media Policy Copyright (C) Terumo Corporation, All Rights Reserved.Disclaimer
Not all of the Terumo products shown on this website are registered in, approved for sale in, or available for purchase in, all countries or regions where this website is accessible. Please consult with your local Terumo representative, distributuion company or customer service center for additional information. Specific indications for use may also vary by country and region. Product images are provided for reference only.* Continue
* Back
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0